



Impact of Workflow Management Systems and Technology Interoperability on Optimizing Medication Safety

APRIL 24, 2022


PRESENTED BY: JENNY RADKE, PHARMD, PGY-2 PHARMACY INFORMATICS RESIDENT

Disclosure Statement


None of the planners for this activity have relevant financial relationships to disclose with ineligible companies.

Objectives

1. Analyze the utility of technology in reducing medication errors with a focus on workflow management systems and Smart pump interoperability
2. Identify the pitfalls of implementing new technology and potential for novel/unexpected errors to occur as a result
3. Evaluate strategies to combat workaround errors that arise for technology-related implementations



Overview





Pre-Questions

1. All of the following statements describe the benefits of implementing a workflow management system, EXCEPT:

- A. Can prevent volume and overflow error by detecting density/weight variations
- B. Allows for image capture to see real-time product preparation
- C. Will always allow for a quicker compounding process due to automation steps
- D. With appropriate use of BCMA, can reduce product/concentration errors

2. Which of the following statements accurately describes the limitations of Smart Pump interoperability?

- A. With interoperability, the wrong concentration and rate would auto-populate into the Smart Pump
- B. Interoperability does not prevent users from manually changing initial dosing parameters
- C. Reliable wireless connection is required to ensure appropriate flow of information
- D. BCMA compliance is unnecessary with interoperability as all information is transmitted wirelessly
- E. B & C

3. Which of the following strategies could be applied to remove hazardous work-arounds during implementation of a new workflow management system?

- A. Educate compounding colleagues about the new process and error reporting
- B. Collaborate with front-line staff to determine barriers causing skipped steps
- C. Apply "in-line verification" or examine real-time digital images of the compounding process
- D. Perform regular safety audits
- E. All of the above

Background

Human errors

- Manual verification of IV products oftentimes insufficient to avoid medication error

2017 ASHP survey

- 26.9% : used barcode scanning for CSP prep/verification
- 64%: omitted automation technology for CSP preparation
- 12.8% : used drug workflow software for CSP prep/verification/dispensing

CSPs of particular interest

High alert medications

- Peds/neonatal products
- Epidural/intrathecal
- Pharmacy-sourced bulk containers

Risk vs. Safety Barriers – A Current Disproportion

Oral medications


- Liquids, tablets, buccal systems

Risk

- Proportionately low
 - Enteral tract defenses
 - Poison control measures
 - Visual inspection of physical drug
 - Unit-Dose packaging

Safety Barriers in Place

- Barcode scanning



Risk vs. Safety Barriers – A Current Disproportion



Intravenous-type medications

- IV, IM, intrathecal, subdural solutions

Risk

- Proportionately high
 - Direct to bloodstream/other sterile area
 - Limited poison control interventions
 - Little/no visual cues for inspection
 - Exponential onset (esp. higher risk meds)

Safety Barriers in Place

- ???

Risk vs. Safety Barriers – A Current Disproportion

Oral medications

- Liquids, tablets, buccal systems

Risk

- Proportionately **low**
 - Enteral tract defenses
 - Poison control measures
 - Visual inspection of physical drug
 - Unit-Dose packaging

Safety Barriers in Place

- Barcode scanning

Intravenous-type medications

- IV, IM, intrathecal, subdural solutions

Risk

- Proportionately **high**
 - Direct to bloodstream/other sterile area
 - Limited poison control interventions
 - Little/no visual cues for inspection
 - Exponential onset (esp. higher risk meds)

Safety Barriers in Place

- ???

Med Safety Goal: Removing Human Error through Technology Interventions

Workflow
Management
Systems
(WFMS)

Smart Pumps &
Interoperability

Med Safety Goal: Removing Human Error through Technology Interventions

Workflow
Management
Systems
(WFMS)

Smart Pumps &
Interoperability

Workflow Management Systems



ISMP Guidance – Minimum Requirements

- Manual inspection not completely effective
- IV Admixture Minimum
 - Barcode Scanning Base Solutions & Ingredients
- Chemotherapy & Pediatric CSPs (ideal)
 - Barcode Scanning
 - Gravimetrics

TECHNOLOGY/AUTOMATION USED FOR COMPOUNDING CSPs

Important note: Data submitted to the ISMP MERP has repeatedly shown that the manual inspection of IV admixtures by pharmacy technicians and pharmacists is not a deterrent in preventing dispensing errors. ISMP believes that the use of technology should be considered the minimum requirement for compounding CSPs. Leadership must support the implementation of technology programs that lack safety features. This includes the implementation of technology programs that lack safety features.

Barcode Scanning

Robotic Image Recognition



Gravimetric Verification

FAQ: If we already have IV w... place to identify ingredi-
ents and base solutions used... ary?

While barcoding does help in... mixture are available, and
imaging allows visualization of... be used to confirm that the
ingredients have actually been... the correct amount.

Workflow Management Systems

- Process Automation & Standardization
 - CSPs: Preparing >> Verifying >> Tracking >> Documenting



Electronic data capture throughout

Pre-Compounding



Barcode Scanning



- Barcode-assisted medication preparation (BCMP)
- Minimum requirement by ISMP
- Barcode scanning each drug, diluent, and base fluid
 - Done before any removal or manipulation of ingredients
 - Reduce product/concentration errors
- Safety benefits dependent on appropriate, consistent use



Compounding



Standardized Workflow

- Standardized steps
 - Standard Operating Procedures (SOPs)
 - Institutional Policies
- Labels auto-generated with appropriate BUD
 - Applied immediately after preparation
 - Follow USP 797, USP 800 (Hazardous)
- Auto-calculations




Real-Time Image Capture

- Image recognition
 - Sequential photo imaging at each step of the compounding process
 - Allowing for prospective verification of each product
 - Retrospective review non-optimal from potential waste viewpoint




Barcode Scanning & Real-time Image Capture – Effect on Errors

- Speth et al. 2013
 - Barcode-intercepted errors: 75%
 - Wrong Drug – 60%
 - Wrong Diluent/Fluid – 28%
 - Wrong Concentration – 12%
 - Pharmacist-rejected errors: 25%
 - Incorrect Drug/Diluent Amount 75%
 - Unclear images or improper technique 25%
 - 2 year BCMP Project
 - 12-week implementation
 - Error rate reduction from 29 to 23 errors/week



Gravimetric Analysis

- Using an electronic balance to weigh solutions, step by step
- Accuracy determined by comparison to verified weight
 - Specific gravity and volume calculations
 - Margin of error limits
 - Prevents volume/overflow errors
- First recommended in ISMP's 2016-2017 Targeted Medication Safety Best Practices for Hospitals



Gravimetric Analysis Effect on Detecting Errors

Reece et al. (2016)

- Ambulatory Pharmacies
- 15,843 doses
- 1,126 errors (7%) detected
 - All **during** compounding
- 12 month study period



34% Production time

- Charts/References in software
- Auto-printing dose/vial labels



37% Pharmacist check time

Error Type	Detected	Detected with Software (n=1126)
Identification errors* Wrong vehicle,		
Weighing deviation • Wrong drug amount		
Vial reconstitution • Wrong diluent amount		
Manual process errors Expired drug vial Calculation error Unspecified mixing error		

Key Findings

- Increased detection of compounding errors (74-fold)
- Accuracy of CSP preparation improved

*via barcode scanning



Caveats to WFMS

“Human factors experts have long warned that each innovation, whether in practice, procedure, drugs, or equipment, carries its own particular set of hazards and, thus, new potential for inducing errors.”

Caveats to WFMS

- Barcode Scanning Errors
 - Recalibration of scanners
 - Training new products (shortages/new drugs)
 - Presence of multiple barcode types per product
 - Visual verification of product / overrides
- Scanning Omitted due to Time trade-off
 - Perceived obstruction to typical workflow
 - Comfortability with visual inspection of products
 - Time constraints at certain times of day (e.g. batches, post-rounds)
- Time/Resource Additions
 - Up to 1.0 FTE to just maintain database (Gravimetrics)
 - Adding FTE hours/resources to maintain efficiency with added safety layer



Caveats to WFMS

Safety Risks During Batching

- Singular Vial Scans
 - Scanning first vial repeatedly
 - Potentially missing erroneous vials
- Decoy products for scanning
 - Bag, vial, syringe specifically for scanning
 - Efficient but risky



Caveats to WFMS

- Pull-back method for syringes
 - Bag injected with drug first
 - Empty syringe filled with air to volume injected
 - Unable to verify actual volume injected



Minnesota BOP prohibits retroactively certifying drug amounts for high alert medications

ASHP Policy #1903: COMPOUNDED STERILE PREPARATION VERIFICATION

*“To advocate that health systems adopt automation and information technology to facilitate in-process and final verification of ... CSPs... [and to] **oppose the use of the syringe pull-back method** or other proxy methods of CSP verification”*

Caveats to WFMS

- New product integration issues
 - Cross scanning of products during drug shortages
- Calculation error due EHR or Compounding Software record errors
 - Ingredient error in → Calculation error out
- Poor image capture quality
 - Similar appearance of full and empty syringes to untrained (and trained) eye
 - Extra time to re-take images / arrange syringes




Figure 1. Volume in syringe may not be easily visualized. The syringe on the right is filled, while the syringe on the left is empty.

Caveats to WFMS

- Gravimetric weighing scale error/failure
 - Laminar flow hood interference and/or vibrations
 - Low volume products most problematic
- Human Error
 - Labeling/Transcription Error
 - Lot number and expiration
 - Confirmation Bias
 - Label swapping post-production



Considerations to Resolve WFMS Work-Arounds/Caveats

- Prioritize highest severity / probability risks with an FMEA
 - Failure mode and effects analysis


Table 2. Failure Modes Identified in IV Workflow Technology^a

Failure Mode	Process Step	Cause	Effect	Severity		Frequency	Detectability	RPN	RHI
				Clinical	Production				
Label does not print or printer malfunction	Product label printed	Software or equipment failure	Troubleshoot printer, redirect label printing, or use Epic label	1	2	2	1	4	4
Incorrect label affixed	Final container removed from scale; final label attached to container	User error	Label will not match product ingredients and/or dose	3	1	1	1	3	3
Error not detected visually ^a	Pharmacist verifies preparation by checking patient information, drug, diluent, photo, and video	User error	Incorrect product dispensed	3	1	3	1	9	9
Pharmacist does not select "DUE"	After confirmation, pharmacist selects "DUE" on system manager and bags final container	User error	No issue with compounding preparation, as preparation would already be completed at this point; pharmacist would not have checked preparation details before releasing to patient	1	2	3	1	6	6

Abbreviations: DUE, drug use evaluation; EMR, electronic medical record; IV, intravenous; RHI, Risk Hazard Index; RPN, Risk Priority Number. Epic refers to EMR system (Epic Systems Corporation, Verona, WI).
^aHighest-risk mode, as determined by RPN and RHI scores of 9.



Considerations to Resolve WFMS Work-Arounds/Caveats



Considerations to Resolve WFMS Work-Arounds/Caveats

Unfamiliarity with Workflow

Hands on training & didactic learning for staff; emphasize risks of workarounds

Omission of WFMS Steps

Internal reporting and pharmacist training to recognize skipped steps

Technique deviation into unsafe practice

Visual auditing and re-certification processes; offer re-training sessions

Equipment issues or interference

Work with third-party vendors to optimize

Considerations to Resolve WFMS Work Arounds /Caveats

When in doubt, throw it out!

Missing documentation

Unclear or omitted digital images

Questionable compounding technique

Reason
Rejected: Other (no pictures taken of the syringes/volume for paclitaxel)

Reason
Rejected: Other (remake w/light protected process)

- Impact of pharmacist final inspection



25% of errors revealed during this stage of the WFMS workflow



Post-Compounding



Dose Tracking & Reduced Waste

Dose Tracking

- Medications tracked through WFMS compounding process & at dispensing

Waste Reduction

- Gravimetric software allows partial vials to be weighed & labeled
- Label with BUD and barcode



Med Safety Goal: Removing Human Error through Technology Interventions

Workflow
Management
Systems
(WFMS)

Smart Pumps &
Interoperability



boundtree.com



BD.com



BBraunusa.com

Smart Pumps & Interoperability



Moogmedical.com




CenturionService.com



Baxter.com


IV Medication Infusion Timeline



*Am J Health Syst Pharm. 2021.
Smart Pumps: Advanced Capabilities and Continuous Quality Improvement. PSQH.com; 2007.
Interoperability Preparedness: What Hospitals Can Do to Be Ready for Smart Pump-EMR Interoperability. PSQH.com; 2016.*

Smart Infusion Pumps

- Coined by ISMP in 2002
- ISMP Guidelines for Optimizing Safe Implement and Use of Smart Infusion Pumps (2018)
- Dose Error Reduction Software (DERS)
- Pre-set parameters – drug type, strength, dosing, etc.



Smart Infusion Pumps – Traditional Workflow

Nurse receives order on the electronic health record (EHR)

Nurse manually enters order information into the Smart Pump

Nurse documents medication start time and order details into the MAR on the EHR



- Medication
- Duration
- Volume
- Rate



MAR medication administration record

Smart Infusion Pumps

- 80% of US hospitals
- Improves dosing compliance
 - Drug library
 - Alert types, frequency of alerts
 - Response to alerts (action)
 - # Overrides
 - Investigation of pump errors
 - Wireless connectivity
 - Updates / data download

Standardize
Infusion
Practices

Dosing Limits

- Soft Limits
- Hard Limits



Smart Infusion Pumps

Study	Population	Key Findings (Pre- vs. Post-implementation)
Rothschild et al. (2005) – Controlled Trial	Cardiac surgical intensive care and step-down units	<ul style="list-style-type: none"> • Bypassing of the drug library (25%) • Overriding alerts including the use of inappropriate boluses <p>Serious medication error rates*: 2.03 and 2.41 ($p = .124$)</p> <p>Rates of preventable ADEs (corrected)*: 0.28 to 0.18 ($p = .27$)</p> <p>Rates of non-intercepted potential ADEs (corrected)*: 2.12 to 0.36 ($p < .0001$)</p>
Ohashi (2014) – Systematic Review	21 studies ⁺ <ul style="list-style-type: none"> • Descriptive observational (10) • RCT (1) • Before–after comparisons (7) 	<ul style="list-style-type: none"> • Medication errors intercepted/recorded (n=12) <ul style="list-style-type: none"> • Wrong rate, wrong dose, pump setting errors • Errors observed (n=10) • ADEs or error reports (n=9) • Smart Pump Compliance Rates: Ranging 62 % to 98 % • Challenge of combining rate of errors caught vs. reduced errors due to technology intervention

Caveats - Smart Infusion Pumps

- Human Error
 - Mis-programming/miscalculation of doses or rates
 - Label admixture / administration instruction confusion
 - Multiple standard concentrations available
 - Custom concentrations (manual entry)
 - Can lack minimum concentration limits




Smart Pumps & Human Factors Engineering


*“Humans can always defeat technology if it is perceived as a barrier. A cardinal human factors design principle is to **make every device user friendly.**”*

The device should save time, not add to it.”

Smart Infusion Pumps – Interoperability Workflow




Interoperability – Effect on Errors



- Skog et al. 2022
- Observational study - community healthcare system
- ***Per 100 infusions (pre- vs. post-implementation):***
 - Total errors: 114.6 vs. 96.5 ($p = 0.02^*$)
 - Administration errors: 41.1 vs. 32.4 ($p = 0.12$)
 - Expired medication errors: 3.1 vs. 0.5 ($p = 0.02^*$)
 - High risk medication errors: 12.8 vs. 6.8 ($p = 0.01^*$)
 - Continuous infusion errors: 12.6 vs. 6.0 ($p = 0.005^*$)

Smart Infusion Pump Limitations

- **Users able to:**
 - Bypass use of the pump or the drug library
 - Override Smart Pump alerts (soft-stops)
- **Smart Pumps rely on medications/limits set in drug library**
 - Maintenance-heavy – customization dependent
- **Important Interoperability Limitations**
 - Dependent on wireless connectivity
 - Re-programmability after initial interface message
 - Still requires BCMA to verify medication used



Managing Smart Infusion Pump Risks

- **Limit orderable concentrations with doses in metric weight/time (vs. mL/hr)**
 - mg/hour, mcg/kg/hour
 - MAR and label match-up
- **Policies & education**
 - Final infusion verification (e.g. low concentrations -> high infusion rates)
 - Smart Pump double checks (e.g. high alert meds)
 - Colleague education
- **Maintenance of drug libraries with limited, standardized concentrations**
 - Remove residual “custom” concentrations
 - Avoid “factor of 10” concentrations



Managing Smart Infusion Pump Risks

- **Focusing on high-impact warnings only**
- **Remove extraneous label information (e.g. prep instructions)**
- **Converting frequently-overridden soft-warnings to hard-warnings**
 - Set hard minimum concentrations
- **Barcode scanning and interoperability**
- **Continuous data analysis**
 - Identifying overridden alerts and barriers



Summary

- **Workflow Management Systems (WFMS) and Smart Pumps (+/- Interoperability)** can improve medication safety in the **preparation** and **administration** stages, respectively
- **Appropriate use of technology** drives safety benefits; workarounds lead to unintended risks/errors
- Forming mitigation strategies for to counteract workarounds is key to maximizing technological benefits





Post-Question

1. All of the following statements describe the benefits of implementing a workflow management system, EXCEPT:

- A. Can prevent volume and overflow error by detecting density/weight variations
- B. Allows for image capture to see real-time product preparation
- C. Will always allow for a quicker compounding process due to automation steps
- D. With appropriate use of BCMA, can reduce product/concentration errors

2. Which of the following statements accurately describes the limitations of Smart Pump interoperability?

- A. With interoperability, the wrong concentration and rate would auto-populate into the Smart Pump
- B. Interoperability does not prevent users from manually changing initial dosing parameters
- C. Reliable wireless connection is required to ensure appropriate flow of information
- D. BCMA compliance is unnecessary with interoperability as all information is transmitted wirelessly
- E. B & C

3. Which of the following strategies could be applied to remove hazardous work-arounds during implementation of a new workflow management system?

- A. Educate compounding colleagues about the new process and error reporting
- B. Collaborate with front-line staff to determine barriers causing skipped steps
- C. Apply "in-line verification" or examine real-time digital images of the compounding process
- D. Perform regular safety audits
- E. All of the above

References

1. Institute for Safe Medication Practices (ISMP). ISMP Targeted Medication Safety Best Practices for Hospitals; 2022. <https://www.ismp.org/guidelines/best-practices-hospitals>.
2. Institute for Safe Medication Practices (ISMP). *ISMP Maximize Benefits of IV Workflow Management Systems by Addressing Workarounds and Errors*; 2017. <https://www.ismp.org/resources/maximize-benefits-iv-workflow-management-systems-addressing-workarounds-and-errors>.
3. American Society of Health-System Pharmacists (ASHP). *ASHP POLICY POSITIONS 1982–2021*. <https://www.ashp.org/-/media/assets/policy-guidelines/docs/browse-by-document-type-policy-positions-1982-2017-with-rationales-pdf.ashx>
4. Institute for Safe Medication Practices (ISMP). *ISMP Guidelines for Safe Preparation of Compounded Sterile Preparations*; 2016. <https://www.ismp.org/guidelines/sterile-compounding>.
5. Speth SL, Fields DB, Schlemmer CB, Harrison C. Optimizing i.v. workflow. *Am J Health Syst Pharm*. 2013;70(23):2076-2080. doi:10.2146/ajhp120738.
6. O'Neal BC, Worden JC, Couldry RJ. Telepharmacy and bar-code technology in an i.v. chemotherapy admixture area. *Am J Health Syst Pharm*. 2009;66(13):1211-1217. doi:10.2146/ajhp080388.
7. Rich, D. Making the Switch to IV Workflow: Automated systems yield benefits, present challenges. *Pharmacy Practice News*. 2016. <https://www.pharmacypracticenews.com/Article/PrintArticle?articleID=38584>.

References

8. Reece KM, Lozano MA, Roux R, Spivey SM. Implementation and evaluation of a gravimetric i.v. workflow software system in an oncology ambulatory care pharmacy. *Am J Health Syst Pharm*. 2016;73(3):165-173. doi:10.2146/ajhp150169.
9. Leape LL. "Smart" pumps: A cautionary tale of human factors engineering. *Crit Care Med*. 2005;33(3):679-680. doi:10.1097/01.ccm.0000155779.07020.9e
10. Minnesota Board of Pharmacy. Revisor of Statutes – Compounding Standards. 2012. <https://www.revisor.mn.gov/rules/pdf/6800.3300/2014-01-18%2008:01:25+00:00>
11. Feemster AA, Augustino M, Duncan R, Khandoobhai A, Rowcliffe M. Use of failure modes and effects analysis to mitigate potential risks prior to implementation of an intravenous compounding technology. *Am J Health Syst Pharm*. 2021;78(14):1323-1329. doi:10.1093/ajhp/zxab179.
12. Vanderveen T. Smart Pumps: Advanced Capabilities and Continuous Quality Improvement. Patient Safety & Quality Healthcare, January/February, 2007. <https://www.psqh.com/janfeb07/smartpumps.html>.
13. Wei W, Coffey W, Adeola M, Abbasi G. Impact of smart pump-electronic health record interoperability on patient safety and finances at a community hospital [published online ahead of print, 2021 Jul 14]. *Am J Health Syst Pharm*. 2021;zxab287. doi:10.1093/ajhp/zxab287.

References

14. Vanderveen T, Wilson N, Moatsos, K, Obsheatz M, . Interoperability Preparedness: What Hospitals Can Do to Be Ready for Smart Pump-EMR Interoperability. *Patient Safety & Quality Healthcare*, December 2016. <https://www.psqh.com/analysis/interoperability-preparedness-what-hospitals-can-do-to-be-ready-for-smart-pump-emr-interoperability/>.
15. Institute for Safe Medication Practices. “Smart” infusion pumps join CPOE and bar coding as important ways to prevent medication errors. <http://www.ismp.org/Newsletters/acutecare/articles/20020207.asp>. Accessed March 1, 2022.
16. Pang RKY, Kong DCM, deClifford JM, Lam SS, Leung BK. Smart infusion pumps reduce intravenous medication administration errors at an Australian teaching hospital. *J Pharm Pract Res*. 2011;41(3):192–5.
17. Institute for Safe Medication Practices (ISMP). *ISMP Guidelines for Optimizing Safe Implementation and Use of Smart Infusion Pumps*; 2020. <https://www.ismp.org/guidelines/safe-implementation-and-use-smart-pumps>.
18. Rothschild JM, Keohane CA, Cook EF, et al. A controlled trial of smart infusion pumps to improve medication safety in critically ill patients. *Crit Care Med*. 2005;33(3):533-540. doi:10.1097/01.ccm.0000155912.73313.cd.
19. Ohashi K, Dalleur O, Dykes PC, Bates DW. Benefits and risks of using smart pumps to reduce medication error rates: a systematic review. *Drug Saf*. 2014;37(12):1011-1020. doi:10.1007/s40264-014-0232-1.

References

20. Institute for Safe Medication Practices (ISMP). *Smart Pump Custom Concentrations Without Hard “Low Concentration” Alerts*; 2012. <https://www.ismp.org/resources/smart-pump-custom-concentrations-without-hard-low-concentration-alerts>.
21. Skog J, Rafie S, Schnock KO, Yoon C, Lipsitz S, Lew P. The Impact of Smart Pump Interoperability on Errors in Intravenous Infusion Administrations: A Multihospital Before and After Study. *J Patient Saf.* 2022;18(3):e666-e671. doi:10.1097/PTS.0000000000000905
22. Institute for Safe Medication Practices. Guidelines for optimizing safe implementation and use of smart infusion pumps. February 10, 2020. <https://www.ismp.org/guidelines/safe-implementation-and-use-smart-pumps>.
23. The Joint Commission. Optimizing smart infusion pump safety with DERS. Sentinel Event Alert, 2021; 63: April 14. <https://www.jointcommission.org/-/media/tjc/documents/resources/patient-safety-topics/sentinel-event/sea-63-smart-infusion-pumps-w-ders-final.pdf>.

Acknowledgements

Lindsey Eick, PharmD, BCPS

Jess Lassiter, PharmD, BCPS, CPPS

Eric Stiverson, PharmD

Monika Wojcik, RPh

Questions?

Email: radke@ohsu.edu



Thank You